Psychosis Associated With Synthetic Cannabinoid Agonists: A Case Series
2011; American Psychiatric Association; Volume: 168; Issue: 10 Linguagem: Inglês
10.1176/appi.ajp.2011.11010176
ISSN1535-7228
AutoresDonald Hurst, George Loeffler, Robert N. McLay,
Tópico(s)Poisoning and overdose treatments
ResumoBack to table of contents Previous article Next article Communications and UpdatesFull AccessPsychosis Associated With Synthetic Cannabinoid Agonists: A Case SeriesDonald Hurst, M.D., George Loeffler, M.D., and Robert McLay, M.D., Ph.D.Donald HurstSan Diego, M.D., George LoefflerSan Diego, M.D., and Robert McLaySan Diego, M.D., Ph.D.Published Online:1 Oct 2011https://doi.org/10.1176/appi.ajp.2011.11010176AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail To the Editor: Recreational use of synthetic cannabinoid agonist-containing compounds, commonly known as "Spice," has become increasingly popular. These products consist of nonpsychoactive plant material coated with varying combinations of synthetic cannabinoid agonists (1). Very little is known about the toxicology and psychiatric effects of these drugs. We present a case report in which the smoking of synthetic cannabinoid agonists precipitated new-onset psychosis.Case ReportTen otherwise healthy men were admitted with new-onset psychosis to the psychiatry ward at the Naval Medical Center San Diego between August and December 2010. The patients were between 21 and 25 years old and had no history of psychosis. One patient reported a family history consistent with a primary psychotic disorder (an aunt). Four patients had auditory hallucinations and two had visual hallucinations, nine had paranoid delusions, six had odd or flat affect, four had thought blocking, six had disorganized speech, seven had disorganized behavior, three had alogia, four had suicidal ideation, six had insomnia, six had psychomotor retardation, three had psychomotor agitation, and two had anxiety. A distinct waxing and waning stuporous appearance was common among these patients. Hospitalizations ranged from 6 to 10 days, and seven of the 10 patients received antipsychotics. Seven of the patients' psychotic symptoms resolved between 5 and 8 days after admission, whereas three patients continued to have psychotic symptoms more than 5 months after presentation. All of the patients in this series stated that they had smoked synthetic cannabinoid products on more than one occasion, ranging from four uses over a 3-week period to daily for 1.5 years. The onset of psychotic symptoms varied from after the fourth use to after more than 1 year of use. All patients denied psychotic symptoms before using synthetic cannabinoid products.Two of these patients had used only synthetic cannabinoids prior to the emergence of their psychotic episodes, whereas the remaining patients had used either marijuana or alcohol along with synthetic cannabinoids. Four of the patients last used marijuana 2 or more weeks before they used the synthetic cannabinoid. The temporal relationship between synthetic cannabinoid consumption and psychotic symptoms was determined from information provided by reports from friends, family members, military command, and the patients themselves. Although the majority of the patients were able to report which brands of synthetic cannabinoid blends they smoked, determining the specific synthetic cannabinoid agonists within these blends would have required analyzing samples of the actual substance that the patient smoked; the contents of these products are not accurately listed, are constantly changing, and may not be detectable in commercially available drug screens. A urine test screened for amphetamines, phencyclidine, cocaine, and marijuana, and we obtained blood alcohol levels for all of the patients at the time of hospital admission. Results of a urine screen were positive for the patients who admitted to recent marijuana use. No other substances were found in the patients' urine, and none had detectable blood alcohol levels. Blood tests for synthetic cannabinoids were obtained, and the results were positive for two patients.DiscussionTo our knowledge, no cases of new-onset psychosis after the use of synthetic cannabinoids have been reported. Two case reports described the reemergence of psychosis following the use of synthetic cannabinoid compounds (2, 3). In one of these cases, the patient had a history of cannabis-induced psychotic episodes (2). A recent article reported that synthetic cannabinoid agonists may precipitate psychosis in vulnerable individuals with known psychotic illness (4). Our case series includes patients with no known psychotic illness who experienced prolonged psychotic episodes after smoking synthetic cannabinoid blends.The protracted presence of psychotic symptoms well beyond acute intoxication—sometimes lasting months—is concerning. Physicians should be aware that the use of synthetic cannabinoids can be associated with psychosis and investigate possible use of synthetic cannabinoids in patients with inexplicable psychotic symptoms.San DiegoThe authors report no financial relationships with commercial interests.The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, the Department of Defense, or the United States Government.Accepted for publication in July 2011.References1. Auwärter V , Dresen D , Weinmann W , Muller M , Putz M , Ferreiros N: Spice and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 2009; 44:832–837Crossref, Medline, Google Scholar2. Müller H , Sperling W , Köhrmann M , Huttner H , Kornhuber J , Maler J: The synthetic cannabinoid spice as a trigger for an acute exacerbation of cannabis-induced recurrent psychotic episodes. Schizophr Res 2010; 118:309–310Crossref, Medline, Google Scholar3. Every-Palmer S: Warning: legal synthetic cannabinoid-receptor agonists such as JWH-018 may precipitate psychosis in vulnerable individuals. Addiction 2010; 105:1859–1861Crossref, Medline, Google Scholar4. Every-Palmer S: Synthetic cannabinoid JW-018 and psychosis: an explorative study. Drug Alcohol Depend 2011; 117:152–157Crossref, Medline, Google Scholar FiguresReferencesCited byDetailsCited byPost-aggression suicide under the influence of new psychoactive substances AMB–FUBINACA and U-47700Legal Medicine, Vol. 56Synthetic cannabis: adverse events reported to the New Zealand Pharmacovigilance Centre6 November 2020 | Clinical Toxicology, Vol. 59, No. 6Catatonia Related to Cannabis and Synthetic Cannabinoids: A Review26 April 2021 | Journal of Dual Diagnosis, Vol. 17, No. 2Exploring the Relationships between Sexual Orientation and Gender Identity and Youth Synthetic Cannabinoid Use22 December 2020 | Substance Use & Misuse, Vol. 56, No. 2Club Drugs and Novel Psychoactive Substances21 September 2020 | , Vol. 1Critical Illness Secondary to Synthetic Cannabinoid Ingestion20 July 2020 | JAMA Network Open, Vol. 3, No. 7Synthetic cannabinoid use in psychiatric patients and relationship to hospitalisation: A retrospective electronic case register study28 February 2020 | Journal of Psychopharmacology, Vol. 34, No. 6Designer drugs: mechanism of action and adverse effects6 April 2020 | Archives of Toxicology, Vol. 94, No. 4Synthetic Cannabinoids (SCs) in Metaphors: a Metaphorical Analysis of User Experiences of Synthetic Cannabinoids in Two Countries6 August 2018 | International Journal of Mental Health and Addiction, Vol. 18, No. 1Child and Adolescent Psychiatric Clinics of North America, Vol. 29, No. 1Synthetic cannabinoid use disorder: an update for general psychiatrists21 January 2019 | Australasian Psychiatry, Vol. 27, No. 3Expert Review of Neurotherapeutics, Vol. 19, No. 12Frontiers in Psychiatry, Vol. 10Phantom menace: novel psychoactive substances and the UK Armed Forces22 June 2018 | Journal of the Royal Army Medical Corps, Vol. 164, No. 6Clinical and analytical experience of the National Poison Control Centre with synthetic cannabinoids7 July 2018 | Archives of Industrial Hygiene and Toxicology, Vol. 69, No. 2European Neuropsychopharmacology, Vol. 28, No. 12Psychiatry Research, Vol. 268Drug Metabolism Reviews, Vol. 50, No. 1Cannabis and Cannabinoid Research, Vol. 3, No. 1International Journal of Mental Health Nursing, Vol. 27, No. 2Journal of Surgery and MedicineFrontiers in Behavioral Neuroscience, Vol. 12Synthetic cannabinoids: the hidden side of Spice drugsBehavioural Pharmacology, Vol. 28, No. 6Spice boys: an exploratory study around novel psychoactive substance use on a male acute wardAdvances in Dual Diagnosis, Vol. 10, No. 3Characteristics associated with synthetic cannabinoid use among patients treated in a public psychiatric emergency setting31 October 2016 | The American Journal of Drug and Alcohol Abuse, Vol. 43, No. 1International Journal of Mental Health and Addiction, Vol. 15, No. 3International Journal of Drug Policy, Vol. 43Journal of Adolescent Health, Vol. 60, No. 5Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 79Trends in Pharmacological Sciences, Vol. 38, No. 3Substance Abuse, Vol. 38, No. 3Frontiers in Psychiatry, Vol. 8Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis28 July 2016 | Journal of Psychopharmacology, Vol. 30, No. 12Prevalence and Correlates of Any and Frequent Synthetic Cannabinoid Use in a Representative Sample of High School Students18 May 2016 | Substance Use & Misuse, Vol. 51, No. 9Drug Testing and Analysis, Vol. 8, No. 10Biological Psychiatry, Vol. 79, No. 7Brain Research Bulletin, Vol. 126Case Reports in Psychiatry, Vol. 2016MMWR. Morbidity and Mortality Weekly Report, Vol. 65, No. 27Clinical Toxicology, Vol. 54, No. 1Clinical Toxicology, Vol. 54, No. 4World Journal of Clinical Pediatrics, Vol. 5, No. 1Synthetic Cannabinoids: The Dangers of Spicing It UpJournal of Psychosocial Nursing and Mental Health Services, Vol. 53, No. 5Legal highs: staying on top of the flood of novel psychoactive substances26 January 2015 | Therapeutic Advances in Psychopharmacology, Vol. 5, No. 2The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects13 January 2015 | Journal of Psychopharmacology, Vol. 29, No. 3Toxicology and Management of Novel Psychoactive Drugs26 September 2014 | Journal of Pharmacy Practice, Vol. 28, No. 1Réanimation, Vol. 24, No. 5Drug and Alcohol Dependence, Vol. 149Drug and Alcohol Dependence, Vol. 157Emergency Medicine Clinics of North America, Vol. 33, No. 4Toxicologie Analytique et Clinique, Vol. 27, No. 1Toxicologie Analytique et Clinique, Vol. 27, No. 1Case Reports in Psychiatry, Vol. 2015Addiction Science & Clinical Practice, Vol. 10, No. 1Clinical Schizophrenia & Related Psychoses, Vol. 8, No. 4Uyuşturucu Maddelerde Yeni Trend Sentetik Kannabinoidler15 December 2014 | The Bulletin of Legal Medicine, Vol. 19, No. 3The Use of Motivational Interviewing in Conjunction With Adapted Dialectical Behavior Therapy to Treat Synthetic Cannabis Use Disorder31 January 2014 | Clinical Case Studies, Vol. 13, No. 6A review of clinical manifestations in adolescent and young adults after use of synthetic cannabinoids10 December 2013 | Journal for Specialists in Pediatric Nursing, Vol. 19, No. 2, Vol. 43Addictive Behaviors, Vol. 39, No. 7Disease-a-Month, Vol. 60, No. 3Drug and Alcohol Dependence, Vol. 144Emergency Medicine Clinics of North America, Vol. 32, No. 1The International Journal of Neuropsychopharmacology, Vol. 17, No. 03Pediatric Emergency Care, Vol. 30, No. 1Psychiatry: Interpersonal and Biological Processes, Vol. 77, No. 2Drug Testing and Analysis, Vol. 5, No. 9-10Human Psychopharmacology: Clinical and Experimental, Vol. 28, No. 4Psychopharmacology, Vol. 228, No. 4Analytical and Bioanalytical Chemistry, Vol. 405, No. 14Journal of Medical Toxicology, Vol. 9, No. 2Journal of Pediatric Health Care, Vol. 27, No. 2Addiction, Vol. 108, No. 3Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 39, No. 2Journal of Child and Adolescent Psychopharmacology, Vol. 22, No. 5Clinical Toxicology, Vol. 50, No. 10Hospital Pharmacy, Vol. 46, No. 12 Volume 168Issue 10 October 2011Pages 1119-1119 Metrics PDF download History Accepted 1 July 2011 Published online 1 October 2011 Published in print 1 October 2011
Referência(s)